0.00Open0.00Pre Close0 Volume0 Open Interest19.00Strike Price0.00Turnover144.18%IV-81.64%PremiumJan 17, 2025Expiry Date8.54Intrinsic Value100Multiplier22DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9390Delta0.0371Gamma1.22Leverage Ratio-0.0086Theta-0.0061Rho-1.14Eff Leverage0.0031Vega
Omeros Stock Discussion
Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA
Omeros (OMER) announced successful results from its narsoplimab pivotal trial for treating transplant-associated thrombotic microangiopathy (TA-TMA). The primary statistical analysis showed that patients treated with narsoplimab had an over 3-fold reduction in mortality risk (hazard ratio = 0.32) compared to untreated p...
No comment yet